Decorative dot pattern background image.
Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image.

Intensity Therapeutics IT-03

Trial Overview

Official Title

A Multicenter, Randomized, Phase III Study to Assess the Efficacy and Safety of INtratumorally Administered INT230-6 (SHAO, VINblastine, CIsplatin) Compared With Standard of Care in Adult participants With Locally Recurrent, InoperaBLE, or Metastatic Soft Tissue Sarcomas - (THE INVINCIBLE-3 TRIAL)

 

Study Purpose

To evaluate the effectiveness of IT-03 compared to the usual treatment of pazopanib, trabectedin or eribulin

 

Diagnosis

Non-uterine leiomyosarcoma; liposarcoma; or pleomorphic sarcoma

Eligibility

Locally recurrent, inoperable or metastatic with disease progression following one to two prior regimens of treatment. 

 

Intervention

Experimental arm: Tumor injected INT230-6 by interventional radiologist

Control arm: standard of care (usual treatment) – pazopanib, trabectedin or eribulin

For more information visit

Clinicaltrials.gov

Key Participation Requirements
Trial Location(s)
Methodist Estabrook Cancer Center
Gender
Male or Female
Age
18 years and Older
Enrollment Status
Pending
Phase
Phase III